Werbung
Deutsche Märkte schließen in 6 Stunden

  • DAX

    17.993,20
    -95,50 (-0,53%)
     

  • Euro Stoxx 50

    4.971,63
    -18,25 (-0,37%)
     

  • Dow Jones 30

    38.460,92
    -42,77 (-0,11%)
     

  • Gold

    2.338,50
    +0,10 (+0,00%)
     

  • EUR/USD

    1,0726
    +0,0025 (+0,24%)
     

  • Bitcoin EUR

    59.739,16
    -2.243,67 (-3,62%)
     

  • CMC Crypto 200

    1.364,87
    -17,70 (-1,28%)
     

  • Öl (Brent)

    82,85
    +0,04 (+0,05%)
     

  • MDAX

    26.324,18
    -21,89 (-0,08%)
     

  • TecDAX

    3.294,63
    -4,97 (-0,15%)
     

  • SDAX

    14.148,40
    -59,23 (-0,42%)
     

  • Nikkei 225

    37.628,48
    -831,60 (-2,16%)
     

  • FTSE 100

    8.090,67
    +50,29 (+0,63%)
     

  • CAC 40

    8.054,17
    -37,69 (-0,47%)
     

  • Nasdaq Compositive

    15.712,75
    +16,11 (+0,10%)
     

SPPI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 1, 2021 in the Class Action Filed on Behalf of Spectrum Pharmaceuticals, Inc. Limited Shareholders

Newsfile Corp.
·Lesedauer: 2 Min.

New York, New York--(Newsfile Corp. - September 24, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) alleging that the Company violated federal securities laws.

Class Period: December 27, 2018 and August 5, 2021
Lead Plaintiff Deadline: November 1, 2021
No obligation or cost to you.

Learn more about your recoverable losses in SPPI:
https://www.kleinstocklaw.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?id=19862&from=5

Spectrum Pharmaceuticals, Inc. NEWS - SPPI NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Spectrum Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WERBUNG

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Spectrum you have until November 1, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Spectrum securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the SPPI lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97629